Dimensional Fund Advisors LP Trims Holdings in Inspire Medical Systems, Inc. $INSP

Key Points

• Dimensional Fund Advisors reduced its Inspire Medical Systems stake by 31.3% in the first quarter, selling 106,727 shares and retaining 234,670 shares valued at approximately $12.1 million. Institutional investors collectively own 94.91% of the company.
• Analyst sentiment remains cautious, with a consensus rating of “Hold” and an average price target of $68. Recent targets range from $39 to $60, while one firm maintained a sell rating.
• Inspire reported quarterly adjusted earnings of $0.14 per share, beating expectations for a $0.24 loss, while revenue of $200.58 million also exceeded forecasts. However, revenue declined 7.6% year over year, and shares opened at $60.12, well below their 52-week high of $147.03.

Dimensional Fund Advisors LP decreased its position in shares of Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 31.3% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 234,670 shares of the company's stock after selling 106,727 shares during the quarter. Dimensional Fund Advisors LP owned 0.81% of Inspire Medical Systems worth $12,102,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of INSP. Principal Financial Group Inc. raised its position in Inspire Medical Systems by 1.0% during the 1st quarter. Principal Financial Group Inc. now owns 126,788 shares of the company's stock worth $6,540,000 after buying an additional 1,269 shares during the last quarter. Fifth Third Bancorp boosted its holdings in shares of Inspire Medical Systems by 1,794.4% in the 1st quarter. Fifth Third Bancorp now owns 6,441 shares of the company's stock valued at $332,000 after acquiring an additional 6,101 shares during the last quarter. New York State Teachers Retirement System increased its stake in shares of Inspire Medical Systems by 9.3% in the first quarter. New York State Teachers Retirement System now owns 23,599 shares of the company's stock worth $1,217,000 after acquiring an additional 2,004 shares during the period. Y Intercept Hong Kong Ltd increased its stake in shares of Inspire Medical Systems by 124.1% in the first quarter. Y Intercept Hong Kong Ltd now owns 158,274 shares of the company's stock worth $8,164,000 after acquiring an additional 87,639 shares during the period. Finally, Leonteq Securities AG lifted its position in Inspire Medical Systems by 187.3% during the first quarter. Leonteq Securities AG now owns 22,812 shares of the company's stock valued at $1,177,000 after purchasing an additional 14,873 shares during the period. Institutional investors and hedge funds own 94.91% of the company's stock.

Analysts Set New Price Targets

INSP has been the topic of several recent research reports. Summit Redstone set a $39.00 price target on shares of Inspire Medical Systems in a report on Friday, May 22nd. JPMorgan Chase & Co. lifted their price objective on Inspire Medical Systems from $54.00 to $60.00 and gave the company a "neutral" rating in a research note on Tuesday, August 4th. Wells Fargo & Company decreased their price objective on Inspire Medical Systems from $70.00 to $56.00 and set an "equal weight" rating for the company in a report on Tuesday, May 5th. Robert W. Baird upped their target price on Inspire Medical Systems from $54.00 to $59.00 and gave the stock a "neutral" rating in a research note on Tuesday, August 4th. Finally, Weiss Ratings reaffirmed a "sell (d)" rating on shares of Inspire Medical Systems in a report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $68.00.

Inspire Medical Systems Stock Performance

Shares of NYSE INSP opened at $60.12 on Friday. The company has a market capitalization of $1.74 billion, a PE ratio of 13.01, a price-to-earnings-growth ratio of 4.57 and a beta of 0.70. The company's fifty day moving average price is $47.64 and its 200 day moving average price is $54.51. Inspire Medical Systems, Inc. has a 1 year low of $38.91 and a 1 year high of $147.03.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The company reported $0.14 earnings per share for the quarter, beating analysts' consensus estimates of ($0.24) by $0.38. The company had revenue of $200.58 million during the quarter, compared to analysts' expectations of $194.72 million. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The firm's revenue for the quarter was down 7.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.45 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. On average, equities analysts expect that Inspire Medical Systems, Inc. will post 1.24 EPS for the current year.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source